Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACHC vs SGRY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACHC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

ACHC Overall Winner 6-Pillar Tally: ACHC 4 – 2 SGRY Matrix Metrics: ACHC 5 – 5 SGRY

As of Nov 20, 2026, Acadia Healthcare Company, Inc. (ACHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACHC carries a Unified Composite Score of 33.1/100 (SELL) at $34.60 (17.0x Forward P/E, 9.8% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin).

  • Defensive Composite Rating Caution: Although ACHC compares more favorably head-to-head, both ACHC (33.1/100 SELL) and SGRY (29.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACHC vs SGRY
ACHC NASDAQ Head-to-Head Winner
Acadia Healthcare Company, Inc.
Services-Specialty Outpatient Facilities, Nec
$34.60
+0.38% 1D
Market Cap $3.2B
TTM Revenue $3.41B
Forward P/E 17.0x
Beta / 30D Vol 0.68β · 61% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 59.0 Mom 36.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.1% over 20 days), RSI 52
RSI-14: 51.8 · SMA20: $34.42 · SMA50: $31.28
SGRY NASDAQ
Surgery Partners, Inc. Common Stock
Services-General Medical & Surgical Hospitals, Nec
$26.78
+0.34% 1D
Market Cap $3.5B
TTM Revenue $3.36B
Forward P/E N/M
Beta / 30D Vol 0.87β · 166% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 24.0 Flow 56.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.5% over 20 days), RSI 84
RSI-14: 84.4 · SMA20: $24.97 · SMA50: $18.56

6-Pillar Scorecard Institutional Category Breakdown (ACHC 4 – 2 SGRY)

Columns: Metric · ACHC · SGRY
1. Valuation Multiples ACHC
Forward P/E 17.0x N/M
Trailing P/E 16.9x N/M
PEG Ratio 1.37x 1.66x
EV / Revenue 1.6x 1.9x
2. Growth & Scale ACHC
Revenue Growth (YoY) +5.1% -0.8%
Earnings Growth (YoY) -5.1% +0.0%
TTM Revenue (USD) $3.41B $3.36B
Market Cap $3.2B $3.5B
3. Profitability & Quality SGRY
Gross Margin 41.0% 22.2%
Operating Margin 9.8% 13.2%
Net Profit Margin -33.1% -2.6%
Return on Equity (ROE) -40.5% 2.1%
4. Balance Sheet & Cash Flow SGRY
Cash Generation (TTM) -$24M $203M
Cash Flow Margin -0.7% 6.0%
Net Cash / Leverage $2.34B Net Debt (1.24x D/E) $2.96B Net Debt (1.99x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHC
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 49.8% (31st %ile) 62.1% (34th %ile)
Put/Call OI Skew 0.39x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ACHC
OpEx & R&D Intensity 31.2% of Rev ($1.06B) 9.0% of Rev ($302M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACHC (5) vs SGRY (5)
Institutional Metric ACHC SGRY Criterion Row Edge
Market Capitalization
Scale
$3.2B $3.5B Larger Scale SGRY
Trailing P/E Ratio
Valuation
16.9x N/M Lower Multiple ACHC
Forward P/E Ratio
Valuation
17.0x N/M Lower Multiple ACHC
Revenue Growth (YoY)
Growth
+5.1% -0.8% Higher Growth ACHC
Operating Margin (TTM)
Profitability
9.8% 13.2% Higher Margin SGRY
Net Profit Margin
Profitability
-33.1% -2.6% Higher Margin SGRY
Return on Equity (ROE)
Capital Efficiency
-40.5% 2.1% Higher ROE SGRY
52-Week Range Position
Momentum
82% ($11–$40) 97% ($11–$27) Stronger Trend SGRY
Beta / 30D Volatility
Risk Regime
0.68β · 61% Vol 0.87β · 166% Vol Lower Realized Risk ACHC
Unified Institutional Score
Composite Signal
33.1 / 100 (SELL) 29.6 / 100 (SELL) Higher Composite ACHC
Trailing 12M Revenue (USD)
Operating Scale
$3.41B $3.36B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
41.0% 22.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.37x PEG · 1.6x EV/Rev 1.66x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.34B Net Debt (1.24x D/E)) $203M ($2.96B Net Debt (1.99x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGRY +59.9 pp
ACHC: +8.53% · SGRY: +68.43%
3M Horizon SGRY +71.5 pp
ACHC: +20.47% · SGRY: +91.97%
6M Horizon SGRY +50.58 pp
ACHC: +49.27% · SGRY: +99.85%
1Y Horizon ACHC +70.82 pp
ACHC: +141.28% · SGRY: +70.46%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACHC Revenue SGRY Revenue ACHC Op. Margin SGRY Op. Margin Margin Leader
FY2018 $1.90B $1.77B 31.2% 4.4% ACHC
FY2019 $2.01B $1.83B 29.2% 12.9% ACHC
FY2020 $2.09B $1.86B -32.2% 9.8% SGRY
FY2021 $2.31B $2.23B 8.2% 13.6% SGRY
FY2022 $2.61B $2.54B 10.5% 13.6% SGRY
FY2023 $2.93B $2.74B -0.7% 12.0% SGRY
FY2024 $3.15B $3.11B 8.1% 11.2% SGRY
FY2025 $3.31B $3.31B -33.3% 11.8% SGRY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACHC CONSOLIDATION
87d in phase · OBV NEUTRAL
Current IV 49.8%
IV Percentile 31st %ile
Put/Call OI Skew 0.39x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ACHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGRY SURGE
5d in phase · OBV NEUTRAL
Current IV 62.1%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGRY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $38.10 · IV 47.7%

ACHC Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,810)

Compare $3,810 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 47.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $35 / $30 Bull Put Spread

Sell 1x $35P · Buy 1x $30P · 59d

Net Entry $112 Credit
Max Credit / Yield +$112 (+28.9% RoM)
Max Risk / Buffer -11.1% Cushion ($388 Mgn)
5d Edge & Liquidity 71% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $40 / $35 Bear Put Spread

Buy 1x $40P · Sell 1x $35P · 31d

Net Entry $220 Debit
T+5d @ -5% Drop +$73 (+33%)
Max Risk / Buffer $220 Capped
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACHC Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.2B market capitalization and 9.8% operating margin.
OpEx & R&D Reinvestment 31.2% of Rev ($1.06B)
90D Engineering Disclosures 0 Published
SGRY Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment 9.0% of Rev ($302M)
90D Engineering Disclosures 0 Published

Investor FAQ ACHC vs SGRY Key Questions & Quantitative Answers

As of Nov 20, 2026, Acadia Healthcare Company, Inc. (ACHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACHC carries a Unified Composite Score of 33.1/100 (SELL) at $34.60 (17.0x Forward P/E, 9.8% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin). Defensive Composite Rating Caution: Although ACHC compares more favorably head-to-head, both ACHC (33.1/100 SELL) and SGRY (29.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

ACHC leads the Growth & Scale pillar: ACHC posts +5.1% YoY revenue growth and -5.1% YoY earnings growth on $3.41B TTM revenue (41.0% gross margin, 9.8% operating margin), compared with SGRY at -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACHC cumulative revenue shifted +74.2% while SGRY shifted +87.0%. In operating R&D and SG&A reinvestment, ACHC deploys 31.2% of Rev ($1.06B) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($302M) (0 disclosures) for SGRY.

ACHC screens cheaper on headline valuation multiples. ACHC trades at 17.0x Forward P/E, 16.9x Trailing P/E, 1.37x PEG, and 1.6x EV/Revenue (-0.7% FCF margin), whereas SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHC (-40.5% ROE) versus SGRY (2.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ACHC carries 49.8% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.68β · 61% Vol realized risk). By comparison, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.